Clinical Trials Logo

Sclerosis clinical trials

View clinical trials related to Sclerosis.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06392126 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

Start date: April 16, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10

NCT ID: NCT06346704 Active, not recruiting - Multiple Sclerosis Clinical Trials

Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis

NHS-MS-EGYPT
Start date: April 25, 2024
Phase:
Study type: Observational

The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis. The Syde® collected data will be compared to on-site conventional clinical endpoints for MS pathology (EDSS, FSS and T25FWT). Subjects with multiple sclerosis will be assessed every 6 months for 2 years.

NCT ID: NCT06310343 Active, not recruiting - Multiple Sclerosis Clinical Trials

ADAs to Alemtuzumab

Start date: April 25, 2022
Phase:
Study type: Observational

The main aim is to quantify the changes in alemtuzumab antibody-anti-alemtuzumab over a 24 months period

NCT ID: NCT06307301 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Study in ALS With Abatacept & IL-2

Start date: October 28, 2021
Phase: Phase 1
Study type: Interventional

In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T-lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. The investigator completed a phase 1 study of infusions of expanded autologous Tregs in combination with subcutaneous IL-2 injections in ALS patients, which showed enhancement of Treg numbers and suppressive function in vivo. The enhanced Treg suppressive function correlated strongly with slowing and stabilization of disease progression. Drugs that enhance endogenous Treg numbers and suppressive function may also stabilize disease in ALS. This phase 1 study aims to determine whether the combination therapy of subcutaneous IL-2 and abatacept (Orencia®) is safe and well-tolerated in 6 patients with ALS, and whether the therapy enhances Treg numbers and suppressive function in vivo.

NCT ID: NCT06280573 Active, not recruiting - Multiple Sclerosis Clinical Trials

COld Exposure With Controlled BReathing And Meditation in Patients With Multiple Sclerosis (COBRAMS)

COBRAMS
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The goal of this interventional study is to test the effect of the anti-inflammatory and neuroprotective effects of this supplementary training program that includes breathing exercises, cold exposure, and meditation in patients diagnosed with multiple sclerosis. Researchers will compare the effect to control groups of MS patients without intervention.

NCT ID: NCT06166043 Active, not recruiting - Multiple Sclerosis Clinical Trials

The Effect of the Nurses Support Program on Fatigue in MS Patient

Start date: January 30, 2023
Phase: N/A
Study type: Interventional

The research will be carried out as a randomized controlled experimental study to examine the effect of a nursing support program supported by a Web-based education program on the management of fatigue symptoms of patients who are under treatment and care in the Multiple Sclerosis clinic of a university hospital.Patients will receive 5 weeks of standard care. At the end of 5 weeks, they will enter a training program. After this online training program, which will be 5 weeks and 2 sessions per week, the change in the patients' fatigue, sleep quality and quality of life will be analyzed.

NCT ID: NCT06133049 Active, not recruiting - Multiple Sclerosis Clinical Trials

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

Start date: March 16, 2021
Phase:
Study type: Observational

The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with multiple sclerosis (MS) who were exposed to ozanimod during pregnancy; the second is women with MS exposed to select other disease-modifying therapies (DMTs) during pregnancy; the third is women with MS not exposed to any DMTs during pregnancy. This study will use data from a large US healthcare claims database.

NCT ID: NCT06121648 Active, not recruiting - Multiple Sclerosis Clinical Trials

Effect of Hydrotherapy on Multiple Sclerosis

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this work was to investigate the effect of a hydrotherapy program on the balance and fatigue of patients with multiple sclerosis. it is a fact that hydrotherapy has an effect on the rehabilitation and treatment of people with balance problems.

NCT ID: NCT06121635 Active, not recruiting - Multiple Sclerosis Clinical Trials

The Effects of Two Types of t-DCS Stimulation on Robot-assisted Gait Training in Patients With Multiple Sclerosis

Start date: December 20, 2022
Phase: N/A
Study type: Interventional

The primary aim of this study is to determine the transcranial direct current stimulation and transcutaneous spinal direct current stimulation in addition to robot-assisted walking training in individuals with Multiple sclerosis; to examine the effects on motor functions against each other and sham application. Secondary aim of this study is to show the relation of these effects with tDCS and ts-DCS through fatigue and quality of life evaluations.

NCT ID: NCT06105463 Active, not recruiting - Multiple Sclerosis Clinical Trials

Multiple Sclerosis, Menstrual Cycle and Physical Acivity

EMMA
Start date: May 6, 2024
Phase: N/A
Study type: Interventional

This study aims to identify moderating variables that modify satisfaction with physical activity practice throughout the menstrual cycle (MC) in women with and without multiple sclerosis (MS) during High-Intensity Interval Training (HIIT) and strength training sessions, and to compare the acute effects of different types of physical activity sessions in women with and without MS. This study used a randomized crossover trial study and single-blind performed by women with MS, matched 1:1 based on age, lifestyle factors and country of residence, with women without MS to analyse the effect of physical activity practise on satisfaction, functionality, fatigue, and inflammatory profile throughout MC. Participants will visit the facilities approximately 10 times (4 preliminary familiarization visits and 6 visits to carry out a physical activity session in each phase of the MC) over a period of 3-4 months. Evaluation will comprise clinical, nutritional and psychological interviews including different variables such as satisfaction on physical activity; visual analogue scale of fatigue; abdominal obesity and anthropometric variables; dietary and nutritional monitoring; bioimpedance analysis; blood profile of hormone, inflammatory and cognitive function blood profile; neuromuscular strength, voluntary activation, and contractile properties; functional assessment (spasticity, knee angles, gait speed, walking endurance, balance, sit-to-stand test, timed up and go test); rating of perceived exertion; pain; muscle oxygen saturation; lactate; heart rate variability; quality of sleep and life; and body temperature. During the luteal phase, women with MS are expected to exhibit different acute responses to HIIT and strength training sessions compared to women without the disease.